Skip to content

Study · Case report or series · n = 1 · 2024

2 results

Semaglutide Treatment in Adult-Onset Autoimmune Diabetes: A Case Study With Long-Term Follow-Up and Periodic Evaluation of Beta-Cell Function.

Da Porto A, Varisco E, Antonello M, Casarsa V, Sechi LA

Cureus8 Mar 2024Cited by 2 (Europe PMC)

PMID38586652 (opens in a new tab)PMCIDPMC10999013 (opens in a new tab)DOI10.7759/cureus.55771 (opens in a new tab)PepBankPUB-38586652
Download PDFPubMedAsk about this study
Jump to 2 results

Summary

Latent autoimmune diabetes of adults (LADA) is a form of autoimmune diabetes that typically occurs in adulthood and has intermediate characteristics between type 1 and type 2 diabetes. To optimize the diagnostic and therapeutic approach, recently, a subclassification of LADA has been proposed based on some clinical features, antibodies, and beta cellular function at onset. In this paper, we expose an interesting case showing the effectiveness of early treatment with a glucagon-like peptide receptor agonist (semaglutide) in maintaining long-term good glycemic control and associated with the preservation of beta-cell function over a five-year observation period in a young woman with LADA.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanCase report or seriesEfficacy outcome

    In a young woman with latent autoimmune diabetes of adults, early semaglutide treatment maintained good glycemic control over five years of observation.

    In plain wordsIn one young woman with adult-onset autoimmune diabetes, early semaglutide was followed by good blood sugar control over five years.

    Peptide
    Semaglutide
    Outcome
    No significant changeLong-term glycemic control
    Study

    n = 1

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · five yearsAs given in this study (human).

    Source sentences

    Summary
    In this paper, we expose an interesting case showing the effectiveness of early treatment with a glucagon-like peptide receptor agonist (semaglutide) in maintaining long-term good glycemic control and associated with the preservation of beta-cell function over a five-year observation period in a young woman with LADA.
    1 context sentence
    Summary · context
    Latent autoimmune diabetes of adults (LADA) is a form of autoimmune diabetes that typically occurs in adulthood and has intermediate characteristics between type 1 and type 2 diabetes.
  2. 02HumanCase report or seriesEfficacy outcome

    In a young woman with latent autoimmune diabetes of adults, early semaglutide treatment was associated with preserved beta-cell function over five years.

    In plain wordsIn one young woman with adult-onset autoimmune diabetes, insulin-making cell function was preserved over five years on semaglutide.

    Peptide
    Semaglutide
    Outcome
    No significant changeBeta-cell function
    Study

    n = 1

    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    Dose not stated · five yearsAs given in this study (human).

    Source sentences

    Summary
    In this paper, we expose an interesting case showing the effectiveness of early treatment with a glucagon-like peptide receptor agonist (semaglutide) in maintaining long-term good glycemic control and associated with the preservation of beta-cell function over a five-year observation period in a young woman with LADA.
    1 context sentence
    Summary · context
    Latent autoimmune diabetes of adults (LADA) is a form of autoimmune diabetes that typically occurs in adulthood and has intermediate characteristics between type 1 and type 2 diabetes.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.